Results 41 to 50 of about 3,726 (180)

Effect of Anti‐IL‐23 and Anti‐IL‐17 Therapy on Darier Disease: A Case Series

Australasian Journal of Dermatology, EarlyView.
ABSTRACT Darier disease is a rare ATP2A2‐related genodermatosis for which therapeutic options remain limited, as acitretin is often constrained by toxicity and teratogenicity. In this retrospective real‐world case series of eight patients, anti‐IL‐17 therapy showed a more consistent early signal of clinical benefit than anti‐IL‐23 therapy, with greater
Maione Vincenzo, Zanghi Silvia, Catapano Cecilia, Bighetti Stefano, Cattaneo Isacco, Venturini Marina, Bettolini Luca   +6 more
wiley   +1 more source

Divergent Paths: A Comprehensive Review of Mechanisms and Clinical Implications in Atopic Dermatitis and Psoriasis

Allergy, EarlyView.
ABSTRACT Atopic dermatitis and psoriasis are two common cutaneous chronic inflammatory diseases. Although they share similar immunological mechanisms, their clinical implications in the patient are different. This review compares both diseases from different points of view such as genetics, natural history, triggers of disease, and skin barrier defects
Tali Czarnowicki, Kazunari Sugita, Zenas Yiu, Sandra Díez‐Ribas, Irene Garcia‐Jimenez, Emma Guttman‐Yassky, Luis F. Santamaria‐Babí   +6 more
wiley   +1 more source

Guselkumab [PDF]

Reactions Weekly, 2020
Deep Joshipura, Brooke Rothstein, David Rosmarin   +2 more
  +4 more sources

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study

Alimentary Pharmacology &Therapeutics, EarlyView.
In a real‐world cohort of patients with highly refractory perianal Crohn's disease, upadacitinib induced clinical remission at 12 months in 26% of patients with fistulizing disease and 25% of those with isolated anal ulcerations. ABSTRACT Introduction Upadacitinib (UPA) is effective for treating luminal Crohn's disease (CD), but data on perianal CD ...
Nicolas Richard, Philippe Seksik, Romain Altwegg, Maria Nachury, David Laharie, Stéphane Nancey, Benoît Coffin, Anne‐Laure Pelletier, Mathieu Uzzan, Aurélien Amiot, Morgane Amil, Lucine Vuitton, Mathurin Fumery, Anne Bozon   +13 more
wiley   +1 more source

Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States

Journal of Dermatological Treatment
Purpose: Real-world data comparing long-term performance of interleukin (IL)-23 and IL-17 inhibitors in psoriasis are limited. This study compared treatment persistence and remission among patients initiating guselkumab versus IL-17 inhibitors.Methods ...
Maryia Zhdanava, Timothy Fitzgerald, Dominic Pilon, Rachel E. Teneralli, Aditi Shah, Lilian Diaz, Patrick Lefebvre, Steven R. Feldman   +7 more
doaj   +1 more source

Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison [PDF]

Anais Brasileiros de Dermatologia
Background: Psoriasis is a chronic inflammatory skin disease with a genetic predisposition and autoimmune component, often treated with immunomodulators such as biologic therapies.
Leyla Baykal Selçuk, Hande Ermiş Akkuş, Burak Akşan, Deniz Aksu Arıca   +3 more
doaj   +1 more source

Cold plasma treatment for oral lichen planus: a retrospective case collection and proposal of a new clinical score

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Oral lichen planus (OLP) is a chronic autoimmune mucosal disease with malignant potential and limited treatment options. This study evaluated the long‐term efficacy and safety of cold atmospheric plasma (CAP) therapy in therapy‐refractory OLP and introduced the novel Lichen Planus Severity Score (LPSS).
Christian Seebauer, Hans‐Robert Metelmann, Mohamed Falougy, Wolfram Kaduk, Lasse Kremer, Georg Daeschlein   +5 more
wiley   +1 more source

S1 Guideline: Therapy of generalized pustular psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Successful long‐term guselkumab treatment of severe plaque psoriasis in patients with class III obesity: A case series

Skin Health and Disease
Data from real‐world studies and clinical trials have documented the long‐term efficacy and safety of guselkumab in patients with moderate‐to‐severe psoriasis.
Marco Galluzzo, Lorenzo Marcelli, Angela Fico, Luca Bianchi, Marina Talamonti   +4 more
doaj   +1 more source

Targeted therapy of psoriasis: inhibition of the IL-23 signaling pathway — evidence from clinical studies and real practice

Vestnik Dermatologii i Venerologii, 2020
The article presents the results of clinical studies of the efficacy and safety of the use of a new drug of genetically engineered biological therapy guselkumab. Guselkumab is the first representative of the interleukin-23 (IL-23) inhibitor class and has
Alkes A. Hotko, Marina Yu. Pomazanova, Larisa Kruglova   +2 more
doaj   +1 more source